ECIO in Palma - An Ablation Lover's Guide

ECIO in Palma - An Ablation Lover's Guide

ECIO 2024 Is upon us! Back by popular demand are the highlights for those of us who eat, drink, and sleep percutaneous tumor ablation. Below are some CASCINATION highlights as well as the "cant-miss" sessions that you should put on your calendar


First of all - we invite you to come by the CASCINATION booth and try something new - our AI Challenge - where participants can challenge themselves vs our AI-driven system to locate an invisible lesion, and assess an ablation zone versus the planned margin. 100 people worldwide have already competed and we are keeping tack of the high scores!


If you are new to learning about Quality Ablation with CAS-One IR, a short video can be found here

Now, for the scientific congress highlights - of notable mention, are 7 abstracts featuring CAS-One IR

It is very challenging to make a "short list" of sessions, but below are the ones that made our cut - we hope you set some calendar reminders for yourself to attend 

Sunday April 28th 

TB 141 - Why an IO should be on the tumor board: HCC
15:00-16:30 Auditorium 1 
  • 141.1 How far have we gotten with Ablation - D. Filippiadis
CF 143 - Meet the PI: upcoming research
15:00-16:30 Auditorium 3 - Moderators: R. Reimer, K. Chapiro
  • 143.6 PROMETHEUS study: a prospective multicenter study on quantitative analysis of ablation margins in HCC - M. Burgmans
CF 151 -Intrahepatic cholangiocarcinoma: what IRs need to know?
17:00-18:30 Auditorium 1 - Moderators: B. Guiu, T. Greten
  • 151.4 Ablation: a place in small ICCs? - B. Odisio
CF 152 -Selecting my best first case: why, when, how
17:00-18:30 Auditorium 2 - Moderators: R. Iezzi, E. Coimbra
  • 152.2 Electrochemotherapy in liver lesions - A. Kovacs
BC 153 - Kidney and adrenal: renal ablation basics 1
17:00-18:30 Auditorium 2 - Moderators: R. Iezzi, E. Coimbra
  • 153.1 Epidemiology: when to treat and when not to treat - M. Muntener
  • 153.2 Biopsy of small renal masses: when and how best done? - L. Tselikas
  • 153.3 Percutaneous renal ablation: best ablation tool and image guidance - R. Cazzato
  • 153.4 Understanding the current outcome data compared to surgery - M. Calandri

Monday April 29th 

CF 211 - Colorectal cancer liver metastases
8:30-10:00 Auditorium 1 - Moderators: A. Cervantes, M. Meijerink
  • 211.1 ESMO guidelines explained: chemo before, after, or not at all for locally treatable disease - A. Cervantes
  • 211.2 Can tumor biology teach us about the best multimodal treatment for oligometastatic disease? D. Arnold
  • 211.3 When to ablate resectable colorectal cancer liver metastases? - M. Meijerink
  • 211.4 When to resect ablatable colroectal cancer liver metastases? U. Cillo
  • 211.5 When to offer SBRT instead of thermal ablation or resection? M. Mayinger
CF 242 Non-small lung cell cancer in 2024
15:00-16:30 Auditorium 2 - Moderators: R. Suh, J. Palussiere
  •  242.4 The role of percutaneous ablation in NSCLC - R. Suh
TB 251 - Why an IO should be on the tumor board- lung
17:00-18:30 Auditorium 1 - Moderators: U. Martens, M. Alireza Hoda
  • 251.1 How do you select the best thermal ablation technique - T. Iguchi
  • 251.2 How to deal with multiple tumors - A. Veltri
  • 251.3 A Review of frequent and rare complications - J. Gaubert
BC 253 - Kidney and adrenal: renal ablation basics 2
15700-19:00 Auditorium 3 - Moderators: G. Schmidt, X Buy
  • 253.1 Follow up imaging after thermal ablation - G. Tsoumakidou
  • 253.2 T1b renal tumor: is there a role for IO? - F. Ridouani
  • 253.3 Complications of renal thermal ablation: how to avoid and manage them - G. Schmidt
  • 253.4 Role of IO in oligometastatic renal cancer - X. Buy  

Tuesday April 30th 

CF311 - Open debates in modern HCC treatment
8:30-10:00 Auditorium 1 - Moderators: D. Arnold, P. Pereira
  • 311.6 AI and HCC: A happy marriage? M. Ronot
CF312 - MSK IO: ablate, palliate and protect
8:30-10:00 Auditorium 2 - Moderators: M. Callstrom, A. Ryan
  • 312.1 Heat-bsed thermal ablation of osseous malignancy - C. Pusceddu
  • 312.2 Cryoablation of musculoskeletal tumors - R. Cazzato
  • 312.3 Electrochemotherapy: current status and role - F. Deschamps 
TB 321 - Why an IO should be on the tumor board: renal cancer
10:30-12:00 Auditorium 1 - Moderators: D. Breen, M. Schmidinger
  • 321.1 Renal cancer ablation: complex decision-making - A. Barnacle
CF 322 - Artificial intelligence for interventional oncology
10:30-12:00 - Moderators F. Gomez Munoz, L. Marti-Bonmati
  • 322.1 AI Basics: what the IO should know - B. Meyer
  • 322.2 The role of image repositories for research on interventional oncology - L. Marti-Bonmati
  • 322.3 Natural language processing in interventional oncology - A. Jimenez-Pastor
  • 322.4 Artificial intelligence in patient selection and treatment planning in interventional oncology - J. Chapiro
  • 322.5 Artificial intelligence in clinical and imaging follow up - R. Beets-Tan
SP 323 - Technical developments and clinical results in the treatment of liver tumors
10:30 - 12:00 Auditorium 3 - Moderators: R. Iezzi, A. Denys
  • 323.3 AI-based ablation zone segmentation for ablative margin assessment during thermal ablation of colorectal liver metastasis: development and initial evaluation - C. Overduin
  • 323.4 Validation of a Mathematic 3D-liver model to Predict the Most Suitable Treatment Option for Colorectal Liver Metastases: Recommendations from the COLLISION and COLDFIRE trial Expert Panel - B. Van den Bemd
CF 343 - Targeting tumors and assessing the results of the treatment
15:00-16:30 Auditorium 3 - Moderators L. Kenny, A. Adam
  • 343.3 How I plan, deliver, and evaluate the technical success of the treatment of large tumors - C. Sofocleous
  • 343.4 Stereotactic thermal ablation: a luxury for the few or a tool for everyone? - R. Bale
BC 353 - Kidney and adrenal ablation
17:00-19:00 Auditorium 3 - Moderators: J. Rivers, X. Buy
  • 353.1 Indications and patient selection for benign and malignant adrenal tumors - R. Grasso
  • 353.2 Technique for adrenal ablation - P. Rao
  • 353.3 Medical environment for adrenal ablation: the anesthesiologist's point of view - J. Rives

Wednesday May 1st

TB 411 - Why an IO should be on the tumor board: metastatic colorectal cancer
8:30-10:00 - Moderators L. Tselikas, M. Meijierink
  • 411.1 The ESMO guidelines - what is missing?
  • 411.2 Resectable vs. potentially resectable lesions - S. Staettner
  • 411.3 IO: first choice or conversion therapy - C. Sofocleous

Good luck trying to prioritize all of these exciting sessions! We will see you there.